The present study was carried out with an objective of preparation and in vitro evaluation of floating tablets of Clarithromycin by using HPMC K4M and HPMC E15LV. The floating tablets were based on effervescent approach using sodium bicarbonate a gas generating agent. The formulated tablets were investigated for the quality control tests such as weight variation, hardness, friability, swelling index, floating lag time, and total floating time. The in vitro release study of the tablets was performed in 0.1 N HCl as a dissolution media. The results of the present study clearly indicates the promising potential of Clarithromycin floating system as an alternative to the conventional dosage and other sustained release formulations. The drug release of optimized formulation was found to follow zero order and Korsmeyer-Peppas kinetic models and r 2 value nearer to one and n value was found to be 0.8420 and 1.0703. Formulation F13 exhibited better Gastroretentive controlled drug release in comparison to other prepared formulation.
Introduction
In the era of advance biomedical technology, we can maximize the therapeutic index of the drug and also minimize the side effects of drug employing drug delivery systems. Consequently, oral route is most preferred route for the administration of drugs because low cost of therapy and ease of administration leads to higher level of patient compliance. Approximately 50% of the drug delivery systems available in the market are oral drug delivery system 1 
.
Gastric emptying of dosage forms is an extremely variable process.
The ability to prolong and control the emptying time is a valuable asset for dosage forms which reside in the stomach for a longer period than conventional dosage forms. Drug absorption from the GIT is a complex procedure and is subject to many variables. The small intestinal transit time is an important parameter for drugs that are incompletely absorbed.
Gastroretentive systems can remain in the gastric region for several hours and hence significantly prolong the gastric residence time of drugs. Prolonged gastric retention improves bioavailability, reduces drug waste and improves solubility for drugs that are less soluble in a high pH environment 2, 3 . It has applications also for local drug delivery to the stomach and proximal small intestine. Gastric retention may increase solubility for the drugs which are poorly soluble in intestine due to alkaline pH before they are emptied, resulting in improved bioavailability. These systems are also advantages in improving GIT absorption of a drug with narrow absorption windows as well as for controlling release of those drugs which are having site specific absorption limitations 4, 5 .
Clarithromycin is a macrolide antibiotic widely prescribed in
Helicobacter pylori mediated peptic ulcers, upper respiratory tract achieve increased gastric residence time for the dosage form and sustained drug release 7, 8 .
Clarithromycin is stable in gastric acidic medium and has a narrow absorption window in gastrointestinal tract, rapid gastrointestinal absorption, highly soluble at acidic pH, no effect of food on absorption and it has higher eradication rate in vivo to H. pylori.
Hence
increasing the gastric retention time of the Clarithromycin in the stomach may improve its bioavailability and therapeutic efficacy. The present study was undertaken to formulate gastroretentive floating tablets of Clarithromycin by using effervescent method.
Materials and Methods

Materials
Clarithromycin were received as gift samples from Cipla Laboratories, Mumbai. HPMC K4M, HPMC, E15LV, sodium bicarbonate and magnesium stearate were received from Colorcon Asia Ltd., Goa.
Preformulation studies of pure drug
Determination of λmax
The solution of Clarithromycin containing concentration of 10 µg/ml was prepared in 0.1N HCl and adding 2ml of Folin Ciocalteau Phenol Reagent (diluted with distilled water in 1:2 ratio) and 2ml of 20% sodium carbonate solution, and UV spectrum was taken using UV spectrophotometer. The sample was scanned in the range of 200-800 cm -1
Preparation of calibration curve in 0.1 N HCl
An accurately weighed amount of Clarithromycin equivalent to 100 mg was dissolved in small amount of 0.1 N HCl in 100 ml volumetric flask and volume made up to 100 ml with the same 0.1 N HCl. From this solution10 ml were withdrawn and diluted up to 100 ml with the 0.1 N HCl in 100 ml volumetric flask to get concentration of 100 µg/ml. From this stock's solution 1 ml, 2 ml, 3 ml, 4 ml, 5 ml, 6 ml, 7 ml, 8 ml, 9 ml and 10 ml were withdrawn and diluted up to 10 ml with Phenol Reagent (diluted with distilled water in 1:2 ratio) and 2 ml of 20% sodium carbonate solution were added to each volumetric flask.
The optical density of every solution was calculated by UV-Visible
Spectrophotometer at 760 nm for Clarithromycin.
Drug polymer compatibility studies
Fourier transforms infrared radiation measurement (FTIR)
FTIR spectra's were recorded on a FTIR spectroscopy using the instrument Shimadzu FT-IR 8400S in the frequency range of 400- 
Differential Scanning Calorimetry (DSC)
Differential Scanning Calorimetry (Perkin Elmer Jade, California, USA) was used for thermal analysis of drug and mixture of drug and excipients in a 1:1 w/w ratio. Individual samples (drug and polymer)
as well as physical mixture of drug and polymer were weighed to about 5 mg in DSC aluminum pan. The sample pan was crimped for effective heat conduction and scanned in the temperature range of 50-300°C. Heating rate of 20°C min-1 was used and the thermogram obtained was reviewed for evidence of any interactions 9, 10 .
Preparation of floating matrix tablets
All the materials were weighed accurately as per formula. At first materials were shifted through 40 no. sieve except magnesium stearate, and it were shifted through 60 mesh. The drug and polymer were mixed properly by geometrical mixing in a double poly bag for few min. Then sodium bicarbonate added to this mixture as a gas generating agent. Mixture once again blended for 5 min. Above mixture had been lubricated with magnesium stearate and mixed for 3 min. Finally mixture was compressed by using punch (18.5 x 9 mm) 11 . The compositions of all formulations are given in table 1.
Evaluation of floating tablets
Weight variation test
20 tablets are taken and their weight is determined individually and collectively on a digital weighting balance. The average weight of one tablet is determined from the collective weight. Note more than 2 of the individual weights may deviate from the average weight by more than the percentage deviation given in the monographs and none should deviate by more than twice that percentage given in the monographs.
Thickness test
The tablets were evaluated for their thickness using a venirer caliper 
Hardness test
Prepared tablets were evaluated for their hardness by using
Monsanto hardness tester. The hardness was measured in terms of kg/cm 2 . Triplicate readings were taken and average was determined.
Friability test
Roche friabilator was used for testing the friability of the tablets. For this test, 20 tablets were weighted accurately and placed in the friabilator chamber and rotated at 25 rpm for a period of 4 min.
Tablets were again weighted and the percentage weight loss was determining by using formula given below.
Where, W1= Weight of tablet before test W2 = Weight of tablet after test. 
Drug content
Three tablets were weighed and ground in a mortar with pestle to get 
In vitro buoyancy studies
The in vitro buoyancy was determined by floating lag time and total floating time. The tablets were placed in a 100 mL beaker containing 
Swelling study
The tablets were weighed individually (designated as W0) and placed separately in petri dish containing 5 mL of 0.1 N HCl and incubated at 37°C ± 1°C. At regular 2 h time intervals until 12 h, the tablets were removed from petri dish, and the excess surface liquid was removed carefully using the tissue paper. The swollen floating tablets were then reweighed (Wt) and % swelling index (SI) was calculated using the following formula:
SI (%)=(Wt−W0/W0)×100.
In vitro dissolution studies
The release rate of CLA from floating tablets (n = 3) was determined 
Kinetic modelling of drug release
To analyze the mechanism of drug release from the floating tablets, the in vitro dissolution data of the formulations were fitted to the zero order, first order, Higuchi model, Hixon Crowell and KorsmeyerPeppas model 15 .
Results and Discussions
Identification of drug by UV spectroscopy
The Clarithromycin was identified by UV spectroscopy method. The
Clarithromycin exhibited maximum absorption at 760 nm. After scanning the λmax of the Clarithromycin at 0.1N HCl does matches with that of the standard λmax of the I.P. This wavelength was considered as λmax for samples and all the observations by UV spectrophotometer to calculate the amount of drug was taken at this wavelength.
Standard curves of Clarithromycin
The standard curve of Clarithromycin was prepared in 0.1N HCl; and results exhibited in table 2. The calibration curve was drawn for Clarithromycin in 0.1N HCl, and it shows straight line in range of concentration from 10 to 100 μg/ml with R 2 value of 0.995 which follows Beer-Lambert law (Fig 1) . The outcomes inferred that belonging to the carbonyl ketone, peak for N-CH3 stretching of aromatic ring at 1424 cm -1 ( Figure 2 ). The IR spectra ofpure drug; drug+HPMC K4M; drug+HPMC E15LV and drug+NaHCO3 for compression showed all the above mentioned peaks for Clarithromycin ( Figure 3) . No major deviation in peaks were obtained in IR spectra, hence this indicates that drug was compatible with other ingredients. The results of IR spectra and DSC thermogram suggest that selection of polymers and NaHCO3 for floating tablets were suitable.
Hence it cannot alter the therapeutics efficacy of Clarithromycin; and it also support to continue further research works. 
Evaluation of postcompression characteristics of floating tablets
Uniform thickness of the tablets throughout the batches ensures good tablet strength and shape and is also important with respect to packaging and handling. The thickness of the tablets should be restricted within 5% or less of an established standard value.
Excessive variation in the tablet thickness can result in problems with packaging as well as consumer acceptance. There was no marked variations in the thickness of tablets within each formulation (<5%)
indicating good flow properties of blend through out the compression process. The thickness of the batches was found in the range of 5.71±0.05 and 5.95±0.08 mm (Table 3) . (Table 3) .
Friability of the tablet is the measure of the tablets strength. Tablets with friability less than 1% of their weight are acceptable. The friability of the formulated floating tablets were in the range of 0.40±0.25 to 0.59±0.09, which was within the specified limits (Table   3) .
A tablet is designed to contain a specific amount of tablet formula. To check labeled amount of drug, it is necessary to note the tablet weight. The average weight of tablets within each formulation was found to be uniform. This indicates uniform filling of the die cavity during tablet compression. The percent deviation in weight variation from average value for all formulations batches were within limit. The weight of the formulated floating tablets was in the range of 765±1.98 to 825±1.15 mg ( Table 3 ).
The data of uniformity of content which was performed by UV spectroscopy indicated that tablets of all batches had drug content within USP limits i.e. between 98.50±1.25 to 102.71±1.10% (Table   3 ). In guidance of industrial scientist different parameter of tablet like dimension hardness, weight variations, drug content etc. were studied which results in successful trials. The drug content of the formulations was found to be within the limits and the value ensures good uniformity of the drug content in the tablets.
Dissolution characteristics of floating tablets
These formulations were analyzed for the floating behavior i.e.
floating lag time and floating time. The result shows that the total floating time for the formulations was more than 12 hours irrespective to the amount of sodium bicarbonate whereas floating lag time decreases with increasing amount of sodium bicarbonate.
The amount of carbon dioxide produced is exclusively proportional to the quantity of sodium bicarbonate in the tablet. Decrease in floating lag time of the formulations can be attributed to the availability of an increased amount of carbon dioxide as the concentration of sodium bicarbonate was increased, being entrapped in the formed gel to give rapid buoyancy. Sodium bicarbonate at the level of 100 mg per tablet showed a floating lag time less than 180 seconds (Table 4) .
Hence, sodium bicarbonate (100 mg per tablet) was essential to achieve optimum in vitro buoyancy.
These formulations were analyzed for the floating behavior i.e. irrespective to the amount of sodium bicarbonate whereas floating lag time decreases with increasing amount of sodium bicarbonate.
Hence, sodium bicarbonate (100 mg per tablet) was essential to achieve optimum in vitro buoyancy. 
Kinetic modelling of drug release
The mechanism of release for the above formulations was the present study it was observed ( Table 5 ) that except F1, F3 and F4 other formulations followed non-Fickian diffusion mechanism, which indicates the drug release through diffusion and relaxation.
From this, best formulation was found to be F13 containing 12% of HPMC K4M. 
Conclusions
From the data obtained, it can be accomplished that, gastroretentive tablet of an antibacterial drug Clarithromycin can be formulated as an advance to increase gastric residence time and thereby improve its bioavailability. Among the polymers used to improve the gastric residence, cellulose polymers (HPMC K4M and HPMC E15LV)
showed better control over drug release. Formulated tablets gave satisfactory results for various physicochemical evaluations for tablets like tablet dimensions, hardness, and weight variation, tablet density, floating lag time, content uniformity and in vitro drug release.
